<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 獲取免費報告) 的股價在週五的午盤交易中下跌了 6%。該公司的股價最低曾達到 9.34 美元，最後交易價為 9.3690 美元。在午盤交易中，共交易了 449,473 股，較平均交易量 1,620,085 股下降了 72%。該股票之前的收盤價為 9.97 美元。</p>
<h2>分析師評級調整</h2>
<p>幾家券商最近對 DAWN 進行了評論。Needham &amp; Company LLC 在 11 月 24 日的研究報告中重申了對 Day One Biopharmaceuticals 的 “買入” 評級，並設定了 16.00 美元的目標價。Weiss Ratings 在週一的報告中重申了對 Day One Biopharmaceuticals 的 “賣出（d-）” 評級。摩根大通將 Day One Biopharmaceuticals 的目標價從 26.00 美元上調至 27.00 美元，並在 11 月 7 日的研究報告中給予該公司 “增持” 評級。Piper Sandler 在 11 月 5 日的研究報告中將 Day One Biopharmaceuticals 的目標價從 25.00 美元上調至 26.00 美元，並給予該股票 “增持” 評級。最後，Zacks Research 在 10 月 13 日的研究報告中將 Day One Biopharmaceuticals 的評級從 “持有” 上調至 “強烈買入”。一位分析師給予該股票 “強烈買入” 評級，七位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，Day One Biopharmaceuticals 目前的平均評級為 “適度買入”，平均目標價為 24.43 美元。</p>
<p><strong>查看我們關於 Day One Biopharmaceuticals 的最新研究報告</strong></p>
<h2>Day One Biopharmaceuticals 價格表現</h2>
<p>該股票的市值為 9.8213 億美元，市盈率為-6.29，貝塔值為-1.27。該股票的 50 日簡單移動平均線為 8.33 美元，200 日簡單移動平均線為 7.38 美元。</p>
<p>Day One Biopharmaceuticals (NASDAQ:DAWN - 獲取免費報告) 最近在 11 月 4 日發佈了季度財報。該公司報告每股收益為-0.19 美元，超出市場共識預期的-0.28 美元，超出幅度為 0.09 美元。Day One Biopharmaceuticals 的淨利潤率為-113.53%，股本回報率為-32.05%。該公司季度收入為 3980 萬美元，而分析師預期為 3820 萬美元。在去年同期，該公司每股收益為 0.38 美元。該公司的收入同比下降了 57.6%。整體來看，分析師預計 Day One Biopharmaceuticals, Inc.在本財年將發佈每股收益-0.72 美元。</p>
<h2>Day One Biopharmaceuticals 內部交易</h2>
<p>在其他 Day One Biopharmaceuticals 的新聞中，內部人士 Adam Dubow 在 11 月 17 日的交易中出售了 4319 股該公司的股票。股票以平均價格 8.91 美元出售，總交易額為 38482.29 美元。交易後，該內部人士持有公司 62626 股，價值 557997.66 美元。此交易代表其持股減少了 6.45%。該交易已在證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上查閲。此外，首席執行官 Jeremy Bender 在 11 月 17 日的交易中出售了 15894 股公司的股票。股票以平均價格 8.91 美元出售，總價值為 141615.54 美元。出售後，首席執行官持有公司 177165 股，價值約 1578540.15 美元。此交易使其持股減少了 8.23%。該出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士已出售 28001 股公司股票，價值 249489 美元。內部人士持有公司股票的比例為 6.20%。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金最近調整了對 DAWN 的持股。Hudson Bay Capital Management LP 在第三季度將其在 Day One Biopharmaceuticals 的持股增加了 1.8%。Hudson Bay Capital Management LP 目前擁有 1320000 股該公司的股票，價值 9306000 美元，在此期間又購買了 23300 股。Tudor Investment Corp ET AL 在第三季度將其在 Day One Biopharmaceuticals 的持股增加了 36.2%。Tudor Investment Corp ET AL 目前擁有 49550 股該公司的股票，價值 349000 美元，在上個季度又購買了 13157 股。PharVision Advisers LLC 在第三季度購買了價值約 299000 美元的 Day One Biopharmaceuticals 新股份。XTX Topco Ltd 在第三季度將其在 Day One Biopharmaceuticals 的持股增加了 224.9%。XTX Topco Ltd 目前擁有 78848 股該公司的股票，價值 556000 美元，在上個季度又收購了 54580 股。最後，Polymer Capital Management US LLC 在第三季度購買了價值約 134000 美元的 Day One Biopharmaceuticals 新股份。機構投資者持有公司 87.95% 的股票。</p>
<h2>Day One Biopharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN 是一家臨牀階段的生物製藥公司，專注於針對腫瘤的靶向療法的發現和開發。該公司採用精準醫療的方法，利用生物標誌物驅動的策略來識別最有可能對其研究化合物產生反應的患者羣體。通過集中關注經過充分驗證的癌症分子驅動因素，Day One 旨在提供具有重要臨牀益處的首創或最佳療法。</p>
<p>該公司的產品管線包括多個處於不同開發階段的小分子候選藥物。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而非 Day One Biopharmaceuticals</li>
<li>電話會議與個人投資者</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
<li>價值投資：在 2022 年這是一個好策略嗎？提示：永遠是</li>
<li>META 在科技下滑中上漲，分析師稱讚特朗普的人工智能命令</li>
<li>2025 年有潛力的兩隻 CRM 平台股票</li>
<li>TL;DR：為什麼 Reddit 是新的增長股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Day One Biopharmaceuticals 嗎？</h2>
<p>在你考慮 Day One Biopharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Day One Biopharmaceuticals 並不在名單上。</p>
<p>雖然 Day One Biopharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DAWN

<p>Day One Biopharmaceuticals 的股票在午盤交易中下跌了 6%，交易量顯著減少。分析師的評級不一，有些對該股票進行了升級，而另一些則進行了下調。內部人士的銷售被報告，機構投資者也調整了他們的持股。該公司報告的季度收益好於預期，但同比收入大幅下降</p>

<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report)'s stock price fell 6% during mid-day trading on Friday . The company traded as low as $9.34 and last traded at $9.3690. 449,473 shares were traded during mid-day trading, a decline of 72% from the average session volume of 1,620,085 shares. The stock had previously closed at $9.97.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 獲取免費報告) 的股價在週五的午盤交易中下跌了 6%。該公司的股價最低曾達到 9.34 美元，最後交易價為 9.3690 美元。在午盤交易中，共交易了 449,473 股，較平均交易量 1,620,085 股下降了 72%。該股票之前的收盤價為 9.97 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several brokerages recently commented on DAWN. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $16.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Day One Biopharmaceuticals in a report on Monday. JPMorgan Chase &amp; Co. raised their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, November 7th. Piper Sandler upped their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday, November 5th. Finally, Zacks Research raised shares of Day One Biopharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $24.43.</p>
<div class="lb-trans"><p>幾家券商最近對 DAWN 進行了評論。Needham &amp; Company LLC 在 11 月 24 日的研究報告中重申了對 Day One Biopharmaceuticals 的 “買入” 評級，並設定了 16.00 美元的目標價。Weiss Ratings 在週一的報告中重申了對 Day One Biopharmaceuticals 的 “賣出（d-）” 評級。摩根大通將 Day One Biopharmaceuticals 的目標價從 26.00 美元上調至 27.00 美元，並在 11 月 7 日的研究報告中給予該公司 “增持” 評級。Piper Sandler 在 11 月 5 日的研究報告中將 Day One Biopharmaceuticals 的目標價從 25.00 美元上調至 26.00 美元，並給予該股票 “增持” 評級。最後，Zacks Research 在 10 月 13 日的研究報告中將 Day One Biopharmaceuticals 的評級從 “持有” 上調至 “強烈買入”。一位分析師給予該股票 “強烈買入” 評級，七位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，Day One Biopharmaceuticals 目前的平均評級為 “適度買入”，平均目標價為 24.43 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Day One Biopharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Day One Biopharmaceuticals 的最新研究報告</strong></p>
</div><h2>Day One Biopharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 價格表現</h2>
</div><p>The stock has a market capitalization of $982.13 million, a P/E ratio of -6.29 and a beta of -1.27. The stock's 50-day simple moving average is $8.33 and its 200 day simple moving average is $7.38.</p>
<div class="lb-trans"><p>該股票的市值為 9.8213 億美元，市盈率為-6.29，貝塔值為-1.27。該股票的 50 日簡單移動平均線為 8.33 美元，200 日簡單移動平均線為 7.38 美元。</p>
</div><p>Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company had revenue of $39.80 million for the quarter, compared to analyst estimates of $38.20 million. During the same period in the prior year, the firm earned $0.38 earnings per share. The company's revenue was down 57.6% on a year-over-year basis. As a group, analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals (NASDAQ:DAWN - 獲取免費報告) 最近在 11 月 4 日發佈了季度財報。該公司報告每股收益為-0.19 美元，超出市場共識預期的-0.28 美元，超出幅度為 0.09 美元。Day One Biopharmaceuticals 的淨利潤率為-113.53%，股本回報率為-32.05%。該公司季度收入為 3980 萬美元，而分析師預期為 3820 萬美元。在去年同期，該公司每股收益為 0.38 美元。該公司的收入同比下降了 57.6%。整體來看，分析師預計 Day One Biopharmaceuticals, Inc.在本財年將發佈每股收益-0.72 美元。</p>
</div><h2>Insider Transactions at Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 內部交易</h2>
</div><p>In other Day One Biopharmaceuticals news, insider Adam Dubow sold 4,319 shares of the firm's stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $38,482.29. Following the transaction, the insider owned 62,626 shares in the company, valued at $557,997.66. This trade represents a 6.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CEO Jeremy Bender sold 15,894 shares of the company's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the sale, the chief executive officer owned 177,165 shares of the company's stock, valued at approximately $1,578,540.15. The trade was a 8.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 28,001 shares of company stock worth $249,489. Insiders own 6.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Day One Biopharmaceuticals 的新聞中，內部人士 Adam Dubow 在 11 月 17 日的交易中出售了 4319 股該公司的股票。股票以平均價格 8.91 美元出售，總交易額為 38482.29 美元。交易後，該內部人士持有公司 62626 股，價值 557997.66 美元。此交易代表其持股減少了 6.45%。該交易已在證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上查閲。此外，首席執行官 Jeremy Bender 在 11 月 17 日的交易中出售了 15894 股公司的股票。股票以平均價格 8.91 美元出售，總價值為 141615.54 美元。出售後，首席執行官持有公司 177165 股，價值約 1578540.15 美元。此交易使其持股減少了 8.23%。該出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士已出售 28001 股公司股票，價值 249489 美元。內部人士持有公司股票的比例為 6.20%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds have recently modified their holdings of DAWN. Hudson Bay Capital Management LP lifted its position in Day One Biopharmaceuticals by 1.8% during the third quarter. Hudson Bay Capital Management LP now owns 1,320,000 shares of the company's stock worth $9,306,000 after purchasing an additional 23,300 shares during the period. Tudor Investment Corp ET AL raised its position in shares of Day One Biopharmaceuticals by 36.2% in the 3rd quarter. Tudor Investment Corp ET AL now owns 49,550 shares of the company's stock valued at $349,000 after buying an additional 13,157 shares in the last quarter. PharVision Advisers LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth approximately $299,000. XTX Topco Ltd boosted its position in shares of Day One Biopharmaceuticals by 224.9% during the 3rd quarter. XTX Topco Ltd now owns 78,848 shares of the company's stock worth $556,000 after acquiring an additional 54,580 shares in the last quarter. Finally, Polymer Capital Management US LLC bought a new position in Day One Biopharmaceuticals in the third quarter valued at approximately $134,000. Institutional investors own 87.95% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近調整了對 DAWN 的持股。Hudson Bay Capital Management LP 在第三季度將其在 Day One Biopharmaceuticals 的持股增加了 1.8%。Hudson Bay Capital Management LP 目前擁有 1320000 股該公司的股票，價值 9306000 美元，在此期間又購買了 23300 股。Tudor Investment Corp ET AL 在第三季度將其在 Day One Biopharmaceuticals 的持股增加了 36.2%。Tudor Investment Corp ET AL 目前擁有 49550 股該公司的股票，價值 349000 美元，在上個季度又購買了 13157 股。PharVision Advisers LLC 在第三季度購買了價值約 299000 美元的 Day One Biopharmaceuticals 新股份。XTX Topco Ltd 在第三季度將其在 Day One Biopharmaceuticals 的持股增加了 224.9%。XTX Topco Ltd 目前擁有 78848 股該公司的股票，價值 556000 美元，在上個季度又收購了 54580 股。最後，Polymer Capital Management US LLC 在第三季度購買了價值約 134000 美元的 Day One Biopharmaceuticals 新股份。機構投資者持有公司 87.95% 的股票。</p>
</div><h2>Day One Biopharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN 是一家臨牀階段的生物製藥公司，專注於針對腫瘤的靶向療法的發現和開發。該公司採用精準醫療的方法，利用生物標誌物驅動的策略來識別最有可能對其研究化合物產生反應的患者羣體。通過集中關注經過充分驗證的癌症分子驅動因素，Day One 旨在提供具有重要臨牀益處的首創或最佳療法。</p>
</div><p>The company's pipeline includes several small-molecule candidates in various stages of development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於不同開發階段的小分子候選藥物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Day One Biopharmaceuticals</li>
<li>Conference Calls and Individual Investors</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>TL;DR: Why Reddit is the New Growth Stock to Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Day One Biopharmaceuticals</li>
<li>電話會議與個人投資者</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
<li>價值投資：在 2022 年這是一個好策略嗎？提示：永遠是</li>
<li>META 在科技下滑中上漲，分析師稱讚特朗普的人工智能命令</li>
<li>2025 年有潛力的兩隻 CRM 平台股票</li>
<li>TL;DR：為什麼 Reddit 是新的增長股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Day One Biopharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Day One Biopharmaceuticals 嗎？</h2>
</div><p>Before you consider Day One Biopharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Day One Biopharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Day One Biopharmaceuticals 並不在名單上。</p>
</div><p>While Day One Biopharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Day One Biopharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Day One Biopharmaceuticals (NASDAQ:DAWN) 的股價下跌了 6% - 接下來會發生什麼？